Want to join the conversation?
As of Dec. 31, 2015, $ZBH had $449.5MM authorized under its $1Bil share repurchase program. Through Feb. 25, 2016, company repurchased about $415MM of shares, including $250MM of shares repurchased from some selling stockholders on Feb. 10. $ZBH expects cash outlays related to Biomet integration to be about $290MM in 2016.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.